Home › Funds › Sofinnova Investments, Inc. › RCUS
Sofinnova Investments, Inc. position in RCUS
ARCUS BIOSCIENCES INC · Health Care
Sofinnova Investments, Inc. reported holding 945,690 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$29.2M, representing 1.55% of its reported portfolio and ranking #23 among its reported holdings. Sofinnova Investments, Inc. has disclosed RCUS holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Sofinnova Investments, Inc.'s RCUS position evolved
Sofinnova Investments, Inc. first disclosed a stake in RCUS in Q1 2025 at 1,037,776 shares (US$8.1M). The position peaked in Q2 2026 at 945,690 shares, worth US$29.2M. Across 6 filings, Sofinnova Investments, Inc. increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 945,690 shares valued at US$29.2M — an increase of 22,604 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 1.04M | $8.15M | New |
| Q2 2025 | 1.22M | $9.90M | Add |
| Q3 2025 | 1.22M | $16.62M | Add |
| Q4 2025 | 1.10M | $26.13M | Reduce |
| Q1 2026 | 923.09K | $19.94M | Reduce |
| Q2 2026 | 945.69K | $29.16M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RCUS and 13F data
RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 46 other funds we track also report a position in RCUS — the largest reported positions include GILEAD SCIENCES, INC. (US$968.8M), MONTANOVA CAPITAL, LLC (US$147.3M), Siren, L.L.C. (US$74.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RCUS
- GILEAD SCIENCES, INC. 31.42M sh · $968.83M · Q2 2026
- MONTANOVA CAPITAL, LLC 4.78M sh · $147.26M · Q2 2026
- Siren, L.L.C. 2.42M sh · $74.62M · Q2 2026
- SAMLYN CAPITAL, LLC 1.55M sh · $47.70M · Q2 2026
- Soleus Capital Management, L.P. 1.17M sh · $36.03M · Q2 2026
- Parkman Healthcare Partners LLC 919.27K sh · $28.34M · Q2 2026
- BAKER BROS. ADVISORS LP 844.82K sh · $26.05M · Q2 2026
- Logos Global Management LP 650.00K sh · $20.04M · Q2 2026
- Ikarian Capital, LLC 504.56K sh · $15.56M · Q2 2026
- Decheng Capital LLC 464.78K sh · $14.33M · Q2 2026
- DAFNA Capital Management LLC 441.83K sh · $13.62M · Q2 2026
- Patient Square Capital LP 355.80K sh · $10.97M · Q2 2026
More on Sofinnova Investments, Inc.
FAQ
How long has Sofinnova Investments, Inc. held RCUS?
Sofinnova Investments, Inc. has disclosed RCUS holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is Sofinnova Investments, Inc.'s current position in RCUS?
As of Q2 2026, Sofinnova Investments, Inc. holds 945.69K shares of RCUS (ARCUS BIOSCIENCES INC), valued at $29.16M, representing 1.55% of its reported portfolio and ranking #23.
Has Sofinnova Investments, Inc. been buying or selling RCUS?
In the latest 13F filing (Q2 2026), Sofinnova Investments, Inc. increased its position in RCUS. The position peaked in Q2 2026 at 945.69K shares.
Which other funds hold RCUS?
Other major institutional holders of RCUS include GILEAD SCIENCES, INC., MONTANOVA CAPITAL, LLC, Siren, L.L.C., among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.